Astellas Oncology C3 Prize
The Astellas Oncology C3 Prize is a grant program by Astellas Pharma Inc. funding non-medicine innovations that improve cancer care, operating as a sub-brand of the global TYO:4503 pharmaceutical company.
- Company typePublic
- Founded2016
- HeadquartersNorthbrook, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What Astellas Oncology C3 Prize does
The Astellas Oncology C3 Prize (Changing Cancer Care Together) is a grant program established in 2016 by Astellas Pharma Inc. to support innovative, non-medicine solutions that improve the cancer care experience for patients, caregivers, and providers. It operates as a sub-brand under Astellas Pharma Inc., a publicly traded Japanese pharmaceutical company headquartered operationally in Northbrook, Illinois, and listed on the Tokyo Stock Exchange (TYO:4503). The C3 Prize specifically funds external entrepreneurs, researchers, and innovators tackling cancer-care challenges outside the core pharmaceutical R&D remit, providing capital, visibility, and access to Astellas' oncology network.
Astellas Pharma's broader parent portfolio encompasses oncology (Xtandi/enzalutamide for prostate cancer, Padcev/enfortumab vedotin for urothelial cancer, Vyloy/zolbetuximab for gastric cancer, Xospata/gilteritinib for AML), transplantation immunology (Prograf, Advagraf XL, Modigraf, Astagraf XL — tacrolimus franchises), urology (Betmiga, Vesicare, Flomaxtra, Vesomni for overactive bladder and BPH), ophthalmology (Izervay/avacincaptad pegol for geographic atrophy), nephrology (Evrenzo/roxadustat for CKD-related anemia), infectious disease (AmBisome, Cresemba, Mycamine), cardiology (Lexiscan), and women's health (Veoza/fezolinetant for vasomotor symptoms). R&D primary focuses include Immuno-Oncology, Genetic Regulation, Targeted Protein Degradation, and Blindness and Regeneration, supported by open-innovation labs (SakuLab-Tsukuba, SakuLab-Cambridge, TME iLab) and digital health accelerators (Rx+ Business Accelerator, HealthX).
Astellas Pharma generates revenue through prescription-medicine sales distributed via regulated pharmaceutical channels — licensed pharmacies, hospitals, and healthcare providers — across more than 19 named countries spanning North America, Europe, Asia Pacific, Latin America, and the Middle East. Pricing is country- and market-specific and not publicly disclosed. The C3 Prize itself is a sponsor-funded grant initiative within this commercial framework, with no disclosed standalone revenue, pricing, or contract structure; its economics consist of grant disbursements drawn from the parent's marketing, CSR, or innovation budget.
Astellas Oncology C3 Prize firmographics
Firmographics- Name
- Astellas Oncology C3 Prize
- Legal name
- Astellas Pharma Inc.
- Website
- https://astellasoncology.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Short description
- The Astellas Oncology C3 Prize is a grant program by Astellas Pharma Inc. funding non-medicine innovations that improve cancer care, operating as a sub-brand of the global TYO:4503 pharmaceutical company.
- Ownership category
- akta.pro rank
Astellas Oncology C3 Prize industry classification
Industry- Product category
- Oncology Innovation Grants
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)
Keywords
Where Astellas Oncology C3 Prize is headquartered
LocationHeadquarters
- HQ city
- Northbrook
- HQ country
- United States
- HQ region
- North America
Markets served
Astellas Oncology C3 Prize business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Distribution channels1 record
Astellas Oncology C3 Prize product offering
Product offeringCore offering
The Astellas Oncology C3 Prize (Changing Cancer Care Together) is a grant program established by Astellas Pharma Inc. to support innovative solutions improving cancer care for patients. It awards grants to innovators, researchers, and entrepreneurs developing novel approaches that address the non-medical challenges faced by cancer patients. Operated as part of Astellas Pharma Inc.'s oncology franchise, it complements the company's broader pharmaceutical portfolio spanning oncology, transplantation, urology, ophthalmology, infectious disease, nephrology, and women's health.
Product overview
Astellas is a global pharmaceutical company that develops and markets a diverse portfolio of prescription medicines across multiple therapeutic areas. The company's products span oncology (including Vyloy, Xospata, Padcev, and Xtandi for various cancers), transplantation immunology (Prograf, Advagraf XL, Modigraf, Astagraf XL for immunosuppression), urology (Betmiga, Vesicare, Flomaxtra, Vesomni for overactive bladder and BPH), ophthalmology (Izervay, Myrbetriq), infectious disease (AmBisome, Cresemba, Mycamine), nephrology (Evrenzo), cardiology (Lexiscan), and women's health (Veoza). Products are available in various formulations including tablets, capsules, injections, and oral suspensions, with availability varying by geographic region. The company maintains a medicines availability transparency portal showing regulated product information across numerous countries.
Differentiator
Problem solved
Functional benefit
Brands
- Astellas Oncology C3 Prize: Changing Cancer Care Together (C3) Prize - an Astellas initiative to support innovative solutions improving cancer care for patients
Products and services
- Astellas Oncology C3 Prize (Changing Cancer Care Together) A grant program that funds and supports innovators, entrepreneurs, and researchers developing novel non-pharmaceutical solutions that address challenges in the cancer care journey, such as patient navigation, care coordination, and quality of life improvements.
- Xtandi (enzalutamide) Androgen receptor inhibitor for the treatment of prostate cancer, available as soft capsules and film-coated tablets.
- Padcev (enfortumab vedotin) Antibody-drug conjugate for the treatment of urothelial cancer, available as powder for concentrate for solution for infusion.
- Xospata (gilteritinib fumarate) Tyrosine kinase inhibitor for the treatment of acute myeloid leukemia (AML), available as film-coated tablets.
- Vyloy (zolbetuximab) Monoclonal antibody for the treatment of gastric cancer, available as powder for concentrate for solution for infusion.
Companies that use Astellas Oncology C3 Prize
Customer profileSegments7 records
Ideal customer profiles2 records
Astellas Oncology C3 Prize technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Astellas Oncology C3 Prize partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights4 records
Astellas Oncology C3 Prize competitors and assessment
Company assessmentDirect peers
- Bristol Myers Squibb: Large oncology-focused pharma with overlapping hematology, immuno-oncology and solid-tumor franchises; relevant peer for Astellas' oncology and transplantation-related immunology work.
- Novartis: Swiss multinational with strong oncology, immunology and cardiovascular/neurology portfolios; competes with Astellas in specialty therapeutics and shares the reimbursement/pricing dynamics in major markets.
- Pfizer: Global pharmaceutical major with a broad oncology portfolio spanning ADCs, kinase inhibitors and biologics; competes with Astellas in prostate, breast and hematology indications.
- AstraZeneca: Global pharma with a deep oncology pipeline across ADCs, PARP inhibitors and bispecifics; competes with Astellas in multiple tumor types and shares the European/US commercial footprint.
- Takeda Pharmaceutical: Largest Japanese peer and fellow Tokyo-listed pharma; shares Japan-domicile macro/dynamic exposure and competes globally in oncology, GI and rare diseases.
- Roche: Oncology and diagnostics major with HER2, hematology and immuno-oncology franchises; overlaps with Astellas' oncology pipeline breadth and shares the European commercial environment.
- Daiichi Sankyo: Japanese oncology-led pharma and a key ADC peer; competes directly with Padcev via Enhertu and other ADC programs overlapping Astellas' solid-tumor strategy.
- Merck & Co. Keytruda-driven oncology leader that shapes the competitive landscape across nearly all Astellas' oncology tumor types through combination therapy positioning.
- Sanofi: Global pharma with oncology, immunology and rare-disease franchises; comparable scale, distribution footprint and exposure to European pricing pressure.
- Johnson & Johnson (Innovative Medicine): Diversified pharma with sizable oncology, immunology and ophthalmology franchises; comparable to Astellas in therapeutic-area breadth and global commercial scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Astellas Oncology C3 Prize social profiles
Digital presenceAstellas Oncology C3 Prize financial estimates
Financial estimateRevenue estimate
Valuation estimate
Astellas Oncology C3 Prize leadership team
Management profileNumber of profiles
Astellas Oncology C3 Prize funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Astellas Oncology C3 Prize M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Astellas Oncology C3 Prize
What does Astellas Oncology C3 Prize do?
The Astellas Oncology C3 Prize (Changing Cancer Care Together) is a grant program established by Astellas Pharma Inc. to support innovative solutions improving cancer care for patients. It awards grants to innovators, researchers, and entrepreneurs developing novel approaches that address the non-medical challenges faced by cancer patients. Operated as part of Astellas Pharma Inc.'s oncology franchise, it complements the company's broader pharmaceutical portfolio spanning oncology, transplantation, urology, ophthalmology, infectious disease, nephrology, and women's health.
Is Astellas Oncology C3 Prize a public or private company?
Astellas Oncology C3 Prize is a public company. It is classified as public and is currently operating.
When was Astellas Oncology C3 Prize founded?
Astellas Oncology C3 Prize was founded in 2016.
Where is Astellas Oncology C3 Prize based?
Astellas Oncology C3 Prize is headquartered in Northbrook, United States, in the North America region.
Who are Astellas Oncology C3 Prize's main competitors?
Direct peers on record are Bristol Myers Squibb, Novartis, Pfizer, AstraZeneca, Takeda Pharmaceutical, Roche, Daiichi Sankyo, Merck & Co., Sanofi and Johnson & Johnson (Innovative Medicine).
Does Astellas Oncology C3 Prize have an API?
No public API is recorded for Astellas Oncology C3 Prize.
What industry is Astellas Oncology C3 Prize in?
Astellas Oncology C3 Prize's product category is Oncology Innovation Grants. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 541714 and its SIC code is 2834.